title: Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell.
abstract: The effect of the group II metabotropic receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), on basal and phencyclidine-induced dopamine efflux were measured in the shell and core subdivisions of the nucleus accumbens--regions which are associated with limbic and motor functions, respectively. Extracellular levels of dopamine were measured using microdialysis in conscious animals, and LY379268 was delivered locally by inclusion in the artificial cerebrospinal fluid (aCSF) flowing through the microdialysis probe. Local administration of LY379268 in the concentration range 10 nM-10 microM reduced basal levels of dopamine in the nucleus accumbens shell, whilst having no effect in the nucleus accumbens core. In the nucleus accumbens shell, basal levels were reduced to approximately 60% compared to the pre-injection control, with a maximal reduction occurring at concentrations of LY379268 > or =100 nM. The response to LY379268 (100 nM) was reversible, with levels returning to baseline following its removal from the aCSF. In a separate experiment, local perfusion of the nucleus accumbens shell with LY379268 (at both 1 and 10 microM) reduced the magnitude of the response to a subsequent systemic administration of phencyclidine (5 mg/kg i.p.). The reduction in the peak dopamine response was only evident with doses of LY379268 that also reduced basal dopamine efflux--LY379268 being ineffective against PCP at 10 nM. However, in animals pre-treated with LY379268 at 1 or 10 microM, PCP still evoked a dopamine response, and in these animals the relative extent of the response was not significantly different between the respective treatment groups. In contrast, in the nucleus accumbens core the magnitude of the dopamine response to PCP was unaffected by local application of LY379268 (at 1 or 10 microM). Our data suggest that within the nucleus accumbens, there exists a distinct regional difference in the control of dopamine release by group II mGluRs, with the nucleus accumbens shell being preferentially affected. Moreover, the selective action of LY379268 on dopamine levels in the nucleus accumbens shell may have implications for the potential antipsychotic activity of group II mGluR agonists.
authors.affiliation: Department of Neuroscience, Eli Lilly and Company Limited, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
authors.forename: Robert G
authors.initials: RG
authors.lastname: Greenslade
authors.forename: Stephen N
authors.initials: SN
authors.lastname: Mitchell
mesh_terms: D000596:Amino Acids / Q000494:pharmacology*; D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D045604:Extracellular Fluid / Q000187:drug effects / Q000502:physiology; D007700:Kinetics; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D010622:Phencyclidine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*
chemical_list: D000596:Amino Acids; D019086:Bridged Bicyclo Compounds, Heterocyclic; C118218:LY 379268; D018094:Receptors, Metabotropic Glutamate; D010622:Phencyclidine; D004298:Dopamine